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MDM2 has been characterized as a protein that binds to and facilitates degradation of the tumor suppressor p53. Interestingly,
more than 40 different splice variants of MDM2 transcripts have been identified both in tumors and normal tissues, and the
majority of these variants do not contain sequence encoding the p53 binding site.This review describes the different splice
forms, the tissues in which they have been identified, and their association with tumor progression and prognosis. In addition,
we discuss the potential functions of these variants and how they interact with full-length MDM2 protein.
Introduction
The first alternatively spliced MDM2 transcripts in human
tumors were identified in 1996 (Sigalas et al., 1996), but only
during the past year have any potential functions been suggest-
ed. A problem that has developed is one of consistency. Even
though most of the splice variant sequences are in GenBank,
some investigators have chosen to give different names to pre-
viously published isoforms. This makes it very difficult to deter-
mine the frequency of occurrence of specific variants or to com-
pare the variants expressed within different tumor histiotypes.
This review briefly summarizes the functions of full-length
MDM2 and then describes all the known MDM2 splice variants
and their potential role in human cancer.
Full-length MDM2
The MDM2 gene was originally isolated from the spontaneously
transformed murine cell line 3T3DM (Cahilly-Snyder et al.,
1987; Fakharzadeh et al., 1991).The human homolog of MDM2,
also referred to as HDM2, was cloned by Oliner et al. (1992)
from the colon carcinoma cell line CaCo-2. Human MDM2 is
amplified and overexpressed in approximately one-third of
human sarcomas, including those of soft tissue and bone.
Combined analysis of data obtained from 3889 tumor samples
from 28 tumor types revealed an overall MDM2 amplification
frequency of 7% (Momand et al., 1998). To date, MDM2 amplifi-
cation has been identified in 19 tumor types with varying fre-
quency. In addition, MDM2 expression can be upregulated inde-
pendent of gene amplification (Landers et al., 1994; Cordon-
Cardo et al., 1994), and oncogenic splice variants have been
identified (Sigalas et al., 1996; Matsumoto et al., 1998; Kraus et
al., 1999; Pinkas et al., 1999; Bartel et al., 2001; Lukas et al.,
2001). Therefore, simple analysis of gene amplification under-
estimates the involvement of MDM2 in human cancer.
The function of MDM2 was unclear until it was demonstrated
to bind to the tumor suppressor p53 and inhibit p53-mediated
transactivation (Momand et al., 1992; Figure 1A). Overexpression
of MDM2 is a mechanism, independent of gene mutation, by
which wild-type p53 function can be inactivated (Chen et al.,
1996; Argentini et al., 2001). MDM2 itself can be upregulated by
p53, generating a negative feedback loop (Wu et al., 1993;
Zauberman et al., 1993). Once MDM2 binds to p53, MDM2 acts
as a ubiquitin ligase and facilitates proteasomal degradation of
p53 (Haupt et al., 1997; Kubbutat et al., 1997; Honda and Yasuda,
2000; Figure 1A).
As well as its p53-dependent functions, MDM2 is part of a
complex network of interactions through which MDM2 affects
the cell cycle, apoptosis, and tumorigenesis. Specific regions of
MDM2 that interact with p53, CBP/p300, pRB, p73, E2F1, DP1,
the L5 ribosomal ribonucleoprotein particle, p14ARF, and RNA
are indicated in Figure 1B. The specific functions of the MDM2
oncoprotein related to the binding of these different proteins
have been discussed in detail in numerous excellent reviews
(Freedman et al., 1999; Momand et al., 2000; Juven-Gershon
and Oren, 1999).
Human tumors containing both mutant p53 and MDM2
amplification are rare (Cordon-Cardo et al., 1994), but the fact
that both modifications can occur within the same tumor and
that two mechanisms to inactivate wild-type p53 are redundant
provides support for a p53-independent function of MDM2. In
addition to its p53-associated functions, MDM2 has been
reported to transform cells, independent of p53. Dubs-
Poterszman et al. (1995) demonstrated transformation of p53
null cells by expression of MDM2, and Jones et al. (1998)
showed that sarcomas develop in the presence or absence of
p53 in MDM2 transgenic mice. The identification of oncogenic
splice variants of human MDM2 transcripts that lack the p53
binding site (Sigalas et al., 1996) provides further evidence of
p53-independent functions of MDM2.
Although considerable evidence suggests that MDM2 has
transforming potential, conflicting data have generated confu-
sion with respect to the oncogenic function of this protein. Two
groups have reported difficulty in transfecting and expressing
full-length MDM2 cDNA in various cell types (Brown et al.,
1998; Kubbutat et al., 1999). These results were unexpected
and inconsistent with the hypothesis that MDM2 is exclusively
an oncogene. Brown et al. (1998) characterized two growth
inhibitory domains within the human MDM2 protein (ID1 and
ID2 in Figure 1B). Deletion of either region allowed stable
expression of MDM2 in NIH3T3 cells and enhanced the tumori-
genic potential of the cells (Brown et al., 1998). Folberg-Blum et
al. (2002) demonstrated that MDM2 overexpression targeted to
the Drosophila wing induced apoptosis of wing imaginal discs,
and Dilla et al. (2000) showed that expression of this protein
promoted apoptosis in medullary thyroid carcinoma cells.
Furthermore, MDM2 is expressed at high levels in terminally dif-
ferentiated tissues such as skin, brain, and muscle (Piette et al.,
1997); such findings are consistent with a growth-inhibitory
antioncogenic phenotype. Potentially, some MDM2 proteins
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encoded by splice variants could display an oncogenic function
that overrides the growth-inhibiting phenotype and/or the apop-
totic phenotype of full-length MDM2 protein. However, data that
suggest a completely opposite function have been described for
several murine MDM2 splice variants, as discussed below
(Dang et al., 2002).
Alternatively and aberrantly spliced variants of MDM2
In addition to mutations and chromosomal aberrations, splicing
of multiple pre-mRNAs is a mechanism by which gene expres-
sion can be regulated or altered. Splicing can occur either “alter-
natively” at intron-exon borders by using genuine donor and
acceptor splice sites, or “aberrantly” at cryptic splice sites within
introns or exons.The usage of different promoters can also gen-
erate alternative transcripts. For example, MDM2 gene tran-
scription can occur from two independent promoters.
Transcripts that arise from the constitutive P1 promoter lack
exon 2, whereas the p53-sensitive P2 promoter generates tran-
scripts lacking exon 1 (Zauberman et al., 1995; Figure 1A).
These mRNAs are identical except for the 5′-untranslated
region (Barak et al., 1994). However, transcription from P2 is
approximately 6-fold greater than that from P1 (Landers et al.,
1997). The proteins derived from these two mRNAs are identi-
cal, as translation begins in exon 3, but the translation of the
shorter P2-derived transcript is more efficient in tumor cells
(Brown et al., 1999).
The analysis of expression of the MDM2 oncogene has
revealed the presence of multiple, differ-
ent sized MDM2 transcripts and MDM2
protein isoforms in NIH3T3 cells (Haines
et al., 1994). After the determination of
the exon-intron structure of the murine
MDM2 gene (Oca Luna et al., 1996), it
was confirmed that two of these tran-
scripts were alternatively spliced.
Different MDM2 isoforms have also been
identified in B cell lymphomas isolated
from Eµ-Myc transgenic mice (Eischen
et al., 1999). Six of these variants have
been characterized, and five were shown
not to encode portions of the p53 binding
domain because of deletions of exons 3,
5, or 4–8 (Dang et al., 2002). The sixth
variant did not contain exon 8 and gener-
ated no protein when a retrovirus con-
taining its cDNA was used to transduce
MEFs. An alternate translation start site
at amino acid 198 was utilized by two of
the variants generating identical N-terminal truncated MDM2
proteins (Dang et al., 2002). Although none of these murine
variants were identical to any found to date in human tumors,
the murine variant V3 demonstrated the most similarity to the
splice variant MDM2-A (Figure 2). MDM2 mRNA transcripts of
3.3, 1.6, and 1.5 kb have been detected in tumors derived from
a murine mammary tumor model, the shorter transcripts having
lost a portion of the C-terminal coding region (Pinkas et al.,
1999).
In human breast carcinoma tissue, transcripts of 6.7, 4.7,
and 1.9 kb have been detected (Pinkas et al., 1999), with the
1.9 kb mRNA lacking exon 12. Western blot analysis of a panel
of human breast carcinomas demonstrated that truncated
MDM2 isoforms of 85, 76, and 57 kDa were expressed in addi-
tion to the full-length 90 kDa protein (Bueso-Ramos et al.,
1996).
A detailed analysis of the MDM2 mRNA in ovarian and blad-
der cancers revealed alternative as well as aberrant splicing
(Sigalas et al., 1996). Sigalas and coworkers have described
five MDM2 transcripts (MDM2-A, -B, -C, -D, and -E in Figure 2)
that lack sequences that encode at least part of the p53 binding
domain, the nuclear localization and export sequences, and the
acidic domain. In vitro expression studies confirmed that the
protein isoforms encoded by four of these splice variants
(MDM2-A, -B, -C, and -D in Figure 2) are unable to bind p53.
Individual or multiple splice variants have also been detected in
glioblastomas (MDM2-A, -B, -C, -D, and -E in Figure 2;
Figure 1. MDM2structure and function
A: Model depicting the well characterized inter-
actions between MDM2 and p53. p53 activates
transcription of MDM2. MDM2 protein in turn
binds to p53 and acts as an E3 ubiquitin ligase
that targets p53 for degradation by the protea-
some, thereby inhibiting its own transcription.
B: Structure of full-length human MDM2 protein
and the cDNA that encodes it. The domains of
the human MDM2 protein and the binding sites
of various proteins are indicated. ID1, ID2:
growth inhibitory domains 1 and 2 (Brown et al.,
1998). NES: nuclear export sequence. NLS:
nuclear localization sequence. NoLS: cryptic
nucleolar localization signal.
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Matsumoto et al., 1998) and glioblastoma cell lines (MDM2-
LN229a, -LN229b, -LN18, -G116, and -G150 in Figure 2; Kraus
et al., 1999). In breast carcinomas, previously described splice
variants and five additional shorter isoforms (MDM2-281bp, 
-219bp, -254bp, -DelE, and -DelF in Figure 2) have been detect-
ed (Lukas et al., 2001; Hori et al., 2000). Another splice variant,
MDM2-Del.G (Hori et al., 2000), which lacks the sequence
between nucleotides 182 and 1432 of the coding region of the
MDM2 mRNA, exactly corresponds to the 219 bp form
described by Lukas et al. (2001).
Screening 87 adult soft-tissue sarcomas (STS), 85 of which
expressed the complete MDM2 coding region, revealed at least
14 additional MDM2 transcripts in 55% of the cases (Bartel et
al., 2001). Of these shorter transcripts, two (MDM2-A and -B in
Figure 2) had been described previously (Sigalas et al., 1996),
whereas the others, to date, are unique to STS (e.g., MDM2-
PM2 and -EU2 in Figure 2). Six additional novel MDM2 splice
variants were identified in primary pediatric rhabdomyosarcoma
tumors and cell lines (MDM2-FB25, -26, -28, -29, -30, and -55 in
Figure 2; Bartel et al., 2002).These variants include alternative-
ly as well as aberrantly spliced forms.
Some of the aberrantly spliced MDM2 transcripts (e.g.,
MDM2-PM2, -EU2, -KB3, and -219bp) have a common splicing
pattern that is illustrated in Figure 3. Splicing occurs at cryptic
splice donor and acceptor sites in regions with high sequence
homology and which occur as many as four times in the coding
region of the MDM2 mRNA. For example, a 10-base repeat
sequence (TGGCCAGTAT in exon 5;TGCCCAGTAT of exon 12)
is involved in the splicing of the KB3 variant (a splice variant
detected in STS; Bartel et al., 2001) and the MDM2-219bp vari-
ant first described by Lukas et al. (2001). In addition to the splic-
ing at repetitive sequences, the splice variant MDM2-DS3
(Bartel et al., 2001) shows another interesting feature. This
splice form contains a novel 87 bp sequence inserted between
exons 4 and 5. Although the function is not known, this
sequence is similar to an α-exon found in the canine MDM2
mRNA (Veldhoen et al., 1999). Therefore, MDM2-DS3 repre-
sents the first identified example of an expressed human MDM2
splice variant that contains α-exon sequence.
In summary, at least 40 alternatively and aberrantly spliced
transcripts of MDM2 mRNA have been identified in tumors, but
it is currently unknown how many of these are actually
expressed as protein. Most variant transcripts lack sequence
that encodes at least part of the p53 binding domain and the
p300 binding domain. The fact that some splice variants have
been detected only in a particular tumor type suggests that they
might contribute to the transformed phenotype of these tumors,
whereas others (e.g., MDM2-B) may be associated with tumori-
genesis in general or be generated as a consequence of the
malignant phenotype.
Relationship of MDM2 expression to tumor stage and
prognosis
Results of clinical studies investigating the association between
MDM2 expression and tumor prognosis are contradictory.
Overexpression of MDM2 in acute lymphoblastic leukemia and
STS is associated with an unfavorable prognosis (Cordon-
Cardo et al., 1994; Gustafsson et al., 1998; Wurl et al., 1998). In
contrast, no relationship has been observed between MDM2
expression in glioblastomas and survival of patients (Newcomb
et al., 1998), and MDM2 gene amplification is a favorable prog-
nostic marker in non-small cell lung carcinoma and STS
Figure 2. Summary of all known MDM2 mRNA splice variants and the
domains that they encode.
MDM2-FL refers to full-length MDM2 mRNA. At least some of the splice vari-
ants, labeled with *, can be translated into protein in vitro.
The sequence that is omitted in most splice forms is highlighted in gray. The
number in parentheses indicates the reference: (1) Sigalas et al., 1996; (2)
Bartel et al., 2001; (3) Bartel et al., 2002; (4) Lukas et al., 2001; (5) Tamborini
et al., 2001; (6) Kraus et al., 1999; (7) Schlott et al., 2001; (8) Hori et al., 2000;
and (9) F.B., unpublished data.
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(Higashiyama et al., 1997; Bartel et al., 2001). In tumors of the
head and neck region, the loss of MDM2 expression is associat-
ed with a poor prognosis (Millon et al., 2001). A potential expla-
nation of these conflicting findings may be that alternatively or
aberrantly spliced MDM2 variants are expressed in certain
tumors and, when present, influence prognosis.
Expression of oncogenic splice forms of MDM2 occurs
more frequently in high-grade than low-grade tumors
(Matsumoto et al., 1998; Bartel et al., 2001). Expression of
aberrantly but not alternatively spliced mRNA in breast carcino-
ma was associated with a shortened overall patient survival
(Lukas et al., 2001), but there was no association with outcome
or survival time for patients with STS that expressed either alter-
natively or aberrantly spliced MDM2 isoforms (Bartel et al.,
2001). In giant cell tumors of the bone, splice variants were
expressed only in stromal cells, not in the giant cells (Evdokiou
et al., 2001). This finding supports the hypothesis that stromal
cells comprise the tumor element in these giant cell tumors.
Unfortunately, studies measuring MDM2 protein expression
have been carried out using different antibodies, several of
which recognize multiple nonspecific proteins in addition to
MDM2. Therefore, the information obtained by measuring total
MDM2 protein in tumors may be of little value, particularly if the
antibodies used for analyses were raised against epitopes not
present within the mutant MDM2 proteins. In order to determine
whether splice variants are expressed, and to evaluate their
relationship to tumorigenesis and prognosis, specific reagents
must be developed.
One could speculate that splice variants of MDM2 exhibit an
antiapoptotic function, which would help explain why some
patients whose tumors contain p53 mutations and overexpress
MDM2 have a worse prognosis than do those whose tumors
have only one of these modifications (Wurl et al., 1998; Figure
4). However, as discussed above, MDM2
has been shown to exhibit a p53-inde-
pendent tumorigenic potential that could
generate an additive growth advantage
in cells expressing mutant p53 (Dubs-
Poterszman et al., 1995; Jones et al.,
1998; Figure 4). It is possible that there
are no splice variants expressed in
tumors where MDM2 amplification is
associated with a good prognosis
(Higashiyama et al., 1997). However,
p53 may also facilitate chemotherapy-
induced apoptosis in such tumors if
MDM2-p53 binding is disrupted (Shieh et
al., 1997; Khosravi et al., 1999; Mayo et
al., 1997). Additional work will be
required to determine which of these
hypotheses are correct.
Functions of the MDM2 isoforms
Although more than 40 splice variants of
MDM2 mRNA have been identified, little
is known about their functions, and it is important to remember
that it is unknown whether all the variant transcripts are translat-
ed into protein. Although most variants have lost internal
sequences, there does not appear to be a common deleted
region that could suggest a common function. Many examples
of alternative splicing force the region encoding the C terminus
to be out-of-frame. This change potentially leads to the genera-
tion of novel amino acid sequences, but because these new
sequences differ in every case, they are unlikely to contribute to
a common novel function of the proteins. The open reading
frames of many variants contain premature stop codons, whose
presence suggests the generation of truncated proteins con-
taining only the N-terminal portion of MDM2.
It is important to note that alternatively and aberrantly
spliced MDM2 mRNAs are usually found together with full-
length MDM2 transcripts. This finding is of interest because
Evans et al. (2001) have demonstrated that at least one splice
variant (MDM2-B, ALT1) can bind to full-length MDM2 protein
and sequester it in the cytoplasm.The splice variant MDM2-B is
the most frequently expressed form in numerous types of can-
cer, including ovarian and bladder cancers (Sigalas et al.,
1996), breast cancer (Matsumoto et al., 1998; Lukas et al.,
2001), STS (Bartel et al., 2001; Tamborini et al., 2001), and
giant cell tumors of the bone (Evdokiou et al., 2001). However,
Evans et al. (2001) also demonstrated that the binding of
MDM2-B to full-length MDM2 increased wild-type p53 activity. A
similar observation was made using the murine splice variants
identified by Dang et al. (2002). Binding of these variants to full-
length MDM2 in MEFs resulted in a release of wild-type p53
such that p53 was not targeted to the proteasome (as shown in
Figure 1A), and was free to mediate growth inhibition as depict-
ed in Figure 4. Expression of splice variants is also associated
with p53 stabilization in glioblastoma cell lines despite amplifi-
Figure 3. Mechanism of aberrant splicing at
repetitive sequences.
MDM2-FL refers to full-length MDM2 mRNA. The
different shaded areas represent the domains
of MDM2 as shown in Figure 1 (see text for
details).
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cation of the MDM2 gene (Kraus et al., 1999), and in STS we
have found a similar correlation between the expression of
MDM2 splice forms and overexpression of p53 (Bartel et al.,
2001). These findings suggest that p53 accumulation arises as
a consequence of alternative as well as aberrant MDM2 splicing
independent of the mutational status of p53.
Most MDM2 splice variants described to date lack
sequence that encodes at least part of the p53 binding domain.
In vitro binding assays have shown that the splice forms MDM2-
A, -B, -C, and -D (Figure 2) lack the ability to bind to and inacti-
vate p53 (Sigalas et al., 1996). Despite the fact that the p53
binding domain is retained in a couple of MDM2 isoforms
(MDM-E, -FB26) which still have the ability to bind p53, MDM2-
mediated degradation of p53 may be inhibited because of the
loss of p300 binding (Zhu et al., 2001). Nevertheless, an
increased amount of wild-type p53 is inconsistent with a poten-
tial transforming phenotype of MDM2 splice variants.
Sigalas et al. (1996) demonstrated that NIH3T3 cells trans-
fected independently with several splice variants could grow as
colonies in soft agar. In support of this transforming function of
MDM2 splice variants, unpublished data from S. Jones et al.
show that MDM2-B can cause tumors in a transgenic mouse
model. In contrast, MDM2-B is expressed in both malignant and
normal mammary tissue (Lukas et al., 2001). It appears that
MDM2 splice variants display different characteristics in differ-
ent cellular backgrounds, as shown in Figure 4. Because it is
unknown under what conditions alternative functions of full-
length MDM2 are active, it is impossible to predict the function
of the splice variants in each model system evaluated.
Each of the numerous MDM2 splice forms could be respon-
sible for a distinct phenotype. For example, some isoforms
encoded by splice variants may lack the ability to bind to p14ARF,
whereas other isoforms might bind to this protein and be
sequestered in the nucleolus (Weber et al., 2000). Furthermore,
the addition of different novel amino acid sequences at the C
terminus might generate novel tumorigenic functions. However,
many splice variants lack the C terminus, a finding that sug-
gests the importance of the N-terminal
portion of the protein. Much work
remains before the functions of MDM2
and its isoforms encoded by alternatively
spliced variants are understood and
before the relationship of this new infor-
mation to the MDM2-p53-p14ARF pathway is clarified.
Conclusions
The MDM2-p53-p14ARF pathway has been elegantly mapped
out by many investigators (including Sherr, 1998), but it now
appears that the pathway may not be as straightforward as orig-
inally thought. Full-length MDM2 displays both oncogenic and
growth inhibitory properties (Figure 4), but how these different
functions are controlled is unknown. It appears as though
MDM2 function may parallel that of MYC. MYC expression
induces apoptosis in cells where the MDM2-p53-p14ARF path-
way is functional (Packham and Cleveland, 1995; Zindy et al.,
1998). Yet, when this pathway is disrupted, the oncogenic phe-
notype of MYC is displayed (Sherr, 1998). Similarly, the con-
trasting functions of full-length MDM2 are probably dependent
upon the genetic background of the cells in which they are
expressed. At least some MDM2 splice variants encode pro-
teins that possess a transforming function both in vitro and in
vivo, but in different model systems, they function to release p53
from full-length MDM2, inducing wild-type p53 activity (Figure
4). Additionally, p53-independent functions of MDM2 and its iso-
forms encoded by alternatively and aberrantly spliced tran-
scripts might be important in tumorigenesis, but it remains to be
seen how these functions are integrated within the well-charac-
terized MDM2-p53-p14ARF tumor surveillance pathway.
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Figure 4. A model suggesting how MDM2 splice
variants with an intact C terminus, for example
MDM2-B, might exhibit contrasting functions.
In normal cells, MDM2 binds to and inhibits the
function of wild-type p53, promoting cell
growth. When MDM2 splice variants are
expressed, they bind to full-length MDM2 pro-
tein, releasing p53, resulting in growth inhibition.
In transformed cells when p53 may be mutated
or not expressed, MDM2 can still promote cell
growth. Under these circumstances, there may
be no consequence of splice variant expres-
sion, because splice variant binding to full-
length MDM2 would not release any wild-type
p53. Under certain conditions, full-length MDM2
expression in a transformed cell results in apop-
tosis or growth inhibition. If splice variants are
expressed in these cells, they may bind and
inhibit the growth-inhibitory function of full-
length protein, resulting in an increased rate of
proliferation.
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